Healthcare consulting is the process of sharing expertise, experiences, giving advice, and guiding healthcare organizations to make informed business decisions that will help to promote growth and provide benefits to their customers and patients.

Dr. C. Omprakash Ph.D., Technical Director & Partner, Vyomus Consulting, holds a Ph.D. in Business Administration and Management and has authored the book Customer Value Proposition: Building a Customer-Centric Business. Currently, he is running Vyomus Consulting which is a science-based, professional consulting, and services firm serving Business to Business (B2B) Customers.

Vyomus advises and helps its customers implement the formation of business structures, operational structures, regulatory strategies, product development strategies, and policies for Pharma, Biotechnology, Medical Devices, CRO, and Life Sciences ITES businesses.

Vyomus works for science-based professional services 

Dr. Omprakash explains how Vyomus Consulting helps Pharmaceuticals, Biopharmaceuticals, Medical Devices, Cosmetics & Specialty Food businesses. “Primarily Vyomus works for science-based professional services to accelerate product commercialization for our customers. What we mean by that is, it means we reduce time to market, accelerate commercialization and make sure all processes are in compliance with what is required to grow their businesses because we do all these things and help our customers grow their business in Biopharmaceuticals, Medical Devices, Cosmetics & Specialty Food businesses that is what we are trying to do,” he says.

We help customers grow their business

Dr. Omprakash sheds light on how Vyomus consulting provides regulatory & product development support to start-up, small to mid-sized, or a global conglomerate. “What we do is we help customers grow their business, matter of fact, Vyomus stands for that. Vyom means progress in Sanskrit and U and S stands for us and our customers – so Vyomus means the progress of our customers. So the primary focus is to ensure that my customer progresses. So what do we mean by that? Progress of our customers means primarily growing our business that is what we define as the progress of our customers. Our services, we have structured right from our name to focus on progressing the business of our customers towards their desired outcomes because of which we have 3 primary services:

Regulatory consulting, Product Development advisory Risk, and Compliance Services.

All these 3 services together are very specific to the regulatory industries which all our customers are in like Pharmaceuticals, Biopharmaceuticals, Medical Devices, Cosmetics, and Specialty Food, all of them are regulated because of which these 3 specific services will help them accelerate their product commercialization and hence commercialize their products faster commit on and which we deliver on and grow their business. So that is how we help our customers’ right from the initial stage till the product commercialization stage,” he says.

Every business challenge is unique 

Dr. Omprakash throws light on the subject of how Vyomus Consulting helps to attain desired business outcomes such as Commercializing products, reducing time to market, Achieving compliance, and Growing business efficiently and effectively. “There are few things which we do differently because our core belief is in that we understand that each and every business challenge is unique and hence each challenge needs to be provided with a solution which is optimal, effective and efficient so as to reach the business objective with which we started off to try and solve the business challenge. Towards that what we do is we approach the whole challenge from 5 primary perspectives:

We understand the science behind the product We understand the business objective –we approach the challenge in solving so that the solution is focused on the business objective primarily. Because of the above two variables, also understand the unique regulatory perspectives under which this product and business objective should be placed. We also have our experience, knowledge comes primarily without which we cannot do anything else or grow.  Also, our in-house proven methodology will ensure that we ultimately help our customers reach their business objectives.

So all these 5 things together will help in giving very unique solution which is optimized and effective and efficient towards the business goal that is why we help them reach from A – Z,” he says.

Dr. Omprakash explains the strategy to Manufacture, Import, Market, and distribute Pharmaceuticals or Biopharmaceuticals or Medical Devices or Cosmetics or Food Products in India,

“What happens is primarily, the solution which we provide to any problem will be based on the type of product and where exactly the business wants to establish itself in terms of the value chain of the regulatory industry be it Pharmaceuticals, Biopharmaceuticals, Medical Devices, Cosmetics & Specialty Food. So primarily the industry works on various permutations and combinations only based on business objectives and business needs on one side like ideation and prototyping value point, prototyping and validating value point, product development value point in the value chain, manufacturing, and marketing value point, even just manufacturing and exporting. The other side is product variability even in biopharmaceuticals it can belong to various segments like a new biological entity, active pharmaceutical ingredient. There are lots of variables also from a product categorization perspective. Now we dive down to the next level where we have to understand how is the product designed, how it interacts, how it helps in demonstrate like a treat, prevent, or diagnose a disease in human beings. It becomes a very unique approach and provides a unique solution to the business objective so this is what we primarily focus to do. Normally what happens is for example let’s say a customer comes to us and says that I want to sell this product and earn money, we try to understand the number of variability and complexities in the market, where exactly they want to position themselves at,  whether they want to manufacture, manufacture and sell, manufacture and export, and so on, then they decide and then we understand the nature of the product and then we go back to them and also say this can also be positioned to be demonstrated in this kind of activity so would you be interested in taking that input as a product development input or do another study or modify the existing study, whether they want to incorporate a wider range of utility or to do something else would require the data to justify the stories when we go and present it to our customers or regulators. This is the kind of thing that typically happens and we approach a business challenge so that there is a lot of clarity from the customer’s perspective when they take a product to the market,” he says.

Need to see is how long the tunnel is

Dr. Omprakash sheds light on how the COVID pandemic and the changes that it will cause from here on, “The new normal is getting redefined today. Previously anybody had to do an audit in the manufacturing unit we had to go there physically and do the diligence. Now we are getting used to doing virtual audits, even regulators accepting as a process across the world. So remote audits are what we are doing and we have pioneered during this pandemic. What is changing the whole dynamics and nature of how we are doing things, but we will have to wait and see what and how we evolve but it is here to stay. Second vaccines are still evolving, there is definitely a light at the end of the tunnel but what we need to see is how long the tunnel is and when we will be able to reach the end of the tunnel,” he says. 

(Edited by Rabia Mistry Mulla)